0001104659-21-076218.txt : 20210603
0001104659-21-076218.hdr.sgml : 20210603
20210603115312
ACCESSION NUMBER: 0001104659-21-076218
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210602
FILED AS OF DATE: 20210603
DATE AS OF CHANGE: 20210603
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Raykov Rosty
CENTRAL INDEX KEY: 0001468316
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32295
FILM NUMBER: 21991759
MAIL ADDRESS:
STREET 1: C/O ADHEREX TECHNOLOGIES INC.
STREET 2: 4620 CREEKSTONE DRIVE, SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FENNEC PHARMACEUTICALS INC.
CENTRAL INDEX KEY: 0001211583
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: PO BOX 13628
STREET 2: 68 TW ALEXANDER DRIVE
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: (919) 636-4530
MAIL ADDRESS:
STREET 1: PO BOX 13628
STREET 2: 68 TW ALEXANDER DRIVE
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER COMPANY:
FORMER CONFORMED NAME: FENNEC PHARMACEUTICALS, INC.
DATE OF NAME CHANGE: 20140903
FORMER COMPANY:
FORMER CONFORMED NAME: ADHEREX TECHNOLOGIES INC
DATE OF NAME CHANGE: 20021223
4
1
tm2118436-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-06-02
0
0001211583
FENNEC PHARMACEUTICALS INC.
FENC
0001468316
Raykov Rosty
68 TW ALEXANDER DRIVE, PO BOX 13628
DURHAM
NC
27709
1
1
0
0
Chief Executive Officer
Stock Option (right to buy)
7.53
2021-06-02
4
A
0
250000
0
A
2031-06-02
Common Shares
250000
250000
D
On June 2, 2021, Rostislav Raykov was granted an incentive stock option to purchase 250,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
1/3 of the shares subject to this option shall vest immediately and may be exercised as of June 2, 2022 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of May 31, 2024 and thereafter, 100% of the total number of shares subject to this option shall be vested.
/s/ Rostislav Raykov, Chief Executive Officer
2021-06-03